⌘K
Loading ticker…
As of 2026-08-21, Protagonist Therapeutics, Inc (PTGX) has a 3-month relative strength percentile of 94 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 76. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.6%, relative volume 0.82×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PTGX is in a stage 2 uptrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 15.0% / 50.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
PTGX is held by 10 ETFs as of May 2026. Top owner: GSSC at 0.08% weight, $830K notional. Top 3 carry $1M.
Held by 32 ETFs · $389M across latest filings · largest weight 2.15% (CAFG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| GSSC | 0.08% | $830K | — |
| AFSM | 0.33% | $325K | — |
| MMSC | 0.41% | $213K | −0.01 pp |
| AFMC | 0.06% | $93K | −0.04 pp |
| ACSG | 0.48% | $82K | −0.02 pp |
| AVUSAvantis U.S. Equity ETF | 0.00% | $43K | new |
| AVLC | 0.00% | $39K | new |
| AVIE | 0.05% | $5K | new |
| GTPE | 0.01% | $3K | — |
| AVTM | 0.00% | $3K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PTGX Jan avg: 5.62% median: 3.50% win: 50% σ: 12.60% n: 4 2022-04-12 → 2026-07-31 | PTGX Feb avg: 13.88% median: 17.02% win: 75% σ: 10.56% n: 4 2022-04-12 → 2026-07-31 | PTGX Mar avg: 20.04% median: 21.56% win: 75% σ: 19.95% n: 4 2022-04-12 → 2026-07-31 | PTGX Apr avg: -17.70% median: -6.10% win: 0% σ: 25.23% n: 5 2022-04-12 → 2026-07-31 | PTGX May avg: 5.61% median: 3.60% win: 80% σ: 7.93% n: 5 2022-04-12 → 2026-07-31 | PTGX Jun avg: 11.78% median: 16.43% win: 80% σ: 13.91% n: 5 2022-04-12 → 2026-07-31 | PTGX Jul avg: 2.60% median: 8.05% win: 60% σ: 20.74% n: 5 2022-04-12 → 2026-07-31 | PTGX Aug avg: 3.50% median: 5.90% win: 75% σ: 11.74% n: 4 2022-04-12 → 2026-07-31 (current) | PTGX Sep avg: -0.44% median: 0.80% win: 50% σ: 12.13% n: 4 2022-04-12 → 2026-07-31 | PTGX Oct avg: 0.87% median: -1.02% win: 50% σ: 13.13% n: 4 2022-04-12 → 2026-07-31 | PTGX Nov avg: 8.23% median: 6.07% win: 50% σ: 14.15% n: 4 2022-04-12 → 2026-07-31 | PTGX Dec avg: 12.26% median: 11.48% win: 50% σ: 23.52% n: 4 2022-04-12 → 2026-07-31 |